Research and Markets - Biopharmaceutical Contract Manufacturing Market (2017-2027) - Characterized By a Number of Blockbuster Therapies (HUMIRA®, RITUXAN®, Lantus®, Avastin®, Herceptin® and REMICADE®

News provided by

Jun 23, 2017, 08:00 ET

DUBLIN, June 23, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Biopharmaceutical Contract Manufacturing Market (2nd Edition), 2017-2027" report to their offering.

Over the years, the biopharmaceutical market has grown into a prominent and promising segment of the overall pharmaceutical industry. Characterized by a number of blockbuster therapies (HUMIRA®, RITUXAN®, Lantus®, Avastin®, Herceptin® and REMICADE®) and a robust pipeline of producttherapy candidates, the market is poised for significant growth in the coming years.

It is worth mentioning that much of the anticipated success of the biopharmaceutical market is dependent on new biologics, which are currently under development, and biosimilars, which are generic versions of these biologics. The field continues to witness significant growth in terms of innovation; this activity is clearly indicative of the growing demand for biologics to cater to existing unmet needs in the industry.

It is necessary to highlight the fact that the development and manufacturing processes for biologics are complex, and usually require advanced capabilities and specialized expertise. In addition, the costs associated with acquiring capabilities in this field are exorbitant and, therefore, it is difficult for companies with limited finances and capacity constraints to succeed by themselves. These complications have led many stakeholders in the biopharmaceutical industry to outsource significant parts of their business operations to contract service providers.

As a result of the above mentioned industry dynamics, the contract manufacturing industry landscape is steadily evolving. CMOs aiming to consolidate their presence in the market are rapidly expanding their service portfolios to provide end-to-end services to their clients and sponsors.

Companies Mentioned

3P Biopharmaceuticals
Aalto Scientific
AbbVie Contract Manufacturing
AbGenomics
Ablynx
Abzena
ACES Pharma
Acticor Biotech
Active Biotech
Adar Biotech
ADC Therapeutics
Adimab
Advanced BioScience Laboratories (ABL)
Advanced Biotherapeutics Consulting (ABC)
Affimed
Affinity Life Sciences
Agensys
Ajinomoto Althea
Albany Molecular Research (AMRI)
Alberta Cell Therapy Manufacturing
(400+ Others)

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. COMPETITIVE LANDSCAPE

5. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN NORTH AMERICA

6. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN EUROPE

7. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN ASIA AND THE REST OF THE WORLD

8. NICHE SECTORS IN BIOPHARMACEUTICAL CONTRACT MANUFACTURING

9. CASE STUDY: OUTSOURCING OF BIOSIMILARS

10. RECENT DEVELOPMENTS

11. CAPACITY ANALYSIS

12. SURVEY ANALYSIS

13. OPPORTUNITY ANALYSIS

14. SWOT ANALYSIS

15. FUTURE OF THE BIOPHARMACEUTICAL CMO MARKET

For more information about this report visit https://www.researchandmarkets.com/research/whhvnh/biopharmaceutical

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets